Miniaturizing screening: how low can we go today?

@inproceedings{Boss2000MiniaturizingSH,
  title={Miniaturizing screening: how low can we go today?},
  author={Roger Boss{\'e} and Chantal Illy and Jack Elands and Daniel Chelsky},
  year={2000}
}
Abstract Miniaturization in HTS is perceived as essential by pharmaceutical screening laboratories to accommodate the enormous increase in compounds and targets over the past few years. The two primary goals are to increase throughput while decreasing costs. However, although the desire is there, what is the reality of being able to achieve these goals? 

Citations

Publications citing this paper.
SHOWING 1-10 OF 10 CITATIONS

The Use of AlphaScreen Technology in HTS: Current Status

  • Current chemical genomics
  • 2008
VIEW 4 EXCERPTS
CITES METHODS & BACKGROUND

High throughput microfluidic system for heterogeneous assays

  • 2005 3rd IEEE/EMBS Special Topic Conference on Microtechnology in Medicine and Biology
  • 2005
VIEW 1 EXCERPT
CITES BACKGROUND